Exelixis, Inc. (EXEL) Down 4.9% — Do I Pack It In Here?
Exelixis, Inc. (EXEL) gave back significant ground in Friday's session, declining 4.86% and shedding $2.72 to close at $53.25 on the NASDAQ. The drop puts fresh pressure on a stock that had only recently reached its 52-week high of $57.57 on July 7, 2026 — meaning shares are now sitting roughly 7.5% below that peak and pulling back from what had been a meaningful multi-month run. The reversal is a reminder that clinical-stage risk can reassert itself quickly, even for companies with established revenue streams.
Trading volume came in at approximately 776,000 shares, a fraction of the 90-day average of roughly 2.54 million. The sharply subdued turnover suggests this was not a panic-driven liquidation event, but the price still gave up nearly five percent on thin participation — a dynamic that warrants attention heading into the next session.
Why Exelixis, Inc. Price is Moving Lower
The dominant weight on EXEL in recent weeks has been the STELLAR-303 colorectal cancer trial for zanzalintinib, the company's key pipeline drug and intended second growth pillar. The final analysis showed the combination with Roche's Tecentriq improved median overall survival to 15.9 months versus 12.7 months for Bayer's Stivarga — a clinically meaningful difference in raw numbers. But the trial failed to reach statistical significance for one of the dual primary endpoints in the critical non-liver-metastases subgroup, and that miss has clouded the regulatory picture considerably. An FDA decision on the NDA remains pending, with a target action date of December 3, 2026, but investors are now pricing in a meaningfully higher risk of a messy or conditional approval rather than a clean commercial green light.
The concern is structural as well as near-term. Exelixis has been openly trying to reduce its heavy dependence on CABOMETYX revenues, and zanzalintinib was supposed to be the vehicle for that transition. A less-than-definitive read from STELLAR-303 weakens the case for a large commercial uptake in colorectal cancer, which had been one of the more attractive potential indications in terms of patient population and competitive dynamics. That pipeline uncertainty lands on top of a mixed Q1 2026 print: net product revenue did grow to $555 million from $513.3 million a year ago, but CABOMETYX revenue of $552.8 million came in below both internal targets and Zacks estimates in the $558 million–564 million range. EPS and net income improved on the back of lower costs and buybacks, but the core franchise missing on the top line is exactly the wrong message to send when the pipeline is simultaneously raising questions.
Adding a technical layer to the fundamental pressure, Exelixis was removed from three Russell 1000 Defensive-style indexes in June 2026. That kind of index exclusion is not a commentary on business quality, but it can force passive funds to reduce or eliminate positions mechanically, adding supply to the market at a time when sentiment is already fragile. Together, the partial clinical miss on STELLAR-303, the CABOMETYX revenue shortfall, and the index-driven outflows have created a difficult confluence of headwinds that explain why the stock has retreated from its July high.
What is the Exelixis, Inc. Rating - Should I Sell?
Weiss Ratings assigns EXEL a B rating. Current recommendation is Buy.
That Buy rating is grounded in a set of fundamentals that remain genuinely strong despite the near-term clinical noise. ROE of 40.99% earns the Excellent Efficiency Index — a standout figure for a pharmaceutical company navigating the capital-intensive business of drug development and commercialization, reflecting how effectively Exelixis converts shareholder equity into earnings even while funding an active pipeline. Revenue growth of 9.97% and a profit margin of 35.08% together support the Excellent Growth Index, demonstrating that CABOMETYX continues to generate substantial cash flow that funds both pipeline investment and ongoing buyback activity. The Excellent Solvency Index adds balance sheet confidence, a meaningful consideration for any biotech-adjacent name facing a multi-year regulatory runway on its next major asset.
The Good Total Return Index and Good Volatility Index occupy the middle of the ratings spectrum, and the volatility designation deserves particular attention given the current backdrop. Clinical binary events — FDA decisions, subgroup analyses, and trial readouts — are inherently difficult to predict, and the STELLAR-303 outcome has already demonstrated how quickly sentiment can shift. A forward P/E of 18.56 is relatively modest for a Health Care name with Exelixis's margin profile, which limits pure valuation downside, but it also prices in a business that remains heavily reliant on a single commercial product while zanzalintinib's regulatory path works itself out through the end of 2026.
Within the Health Care sector, Exelixis sits alongside Eli Lilly and Company (LLY, B) and Johnson & Johnson (JNJ, B) at the top tier of the peer group, and ahead of Amgen Inc. (AMGN, B-), Gilead Sciences, Inc. (GILD, B-), and Vertex Pharmaceuticals Incorporated (VRTX, B-). That relative positioning reflects the strength of Exelixis's profitability and balance sheet metrics, even as the pipeline uncertainty warrants careful monitoring in the months ahead.
About Exelixis, Inc.
Exelixis, Inc. (EXEL) is a Health Care company focused on the discovery, development, and commercialization of oncology therapies. The company's commercial foundation rests on CABOMETYX (cabozantinib), a tyrosine kinase inhibitor approved across multiple cancer indications including renal cell carcinoma and hepatocellular carcinoma. CABOMETYX has established itself as a meaningful competitor in these markets through demonstrated survival benefits and a broad label that supports use across different lines of therapy, and it remains the primary driver of Exelixis's revenue base.
Beyond its commercial franchise, Exelixis is building a pipeline designed to reduce concentration risk around a single asset. Zanzalintinib is the most advanced next-generation candidate, a next-generation multi-kinase inhibitor being evaluated across several tumor types including colorectal cancer through the STELLAR-303 trial and additional studies. The company has pursued a combination strategy — pairing zanzalintinib with checkpoint inhibitors and other agents — to broaden the potential addressable patient population and generate differentiated clinical data relative to existing standards of care.
Exelixis benefits from a strong intellectual property position around its kinase inhibitor portfolio and has established partnerships with major pharmaceutical companies that provide both validation and additional resources. The company's high profit margins reflect a commercial infrastructure that leverages CABOMETYX's established market position efficiently, while ongoing investment in clinical development is supported by the cash flows generated by that franchise. Its focus on oncology — a therapeutic area characterized by significant unmet need and premium pricing dynamics — provides a structural backdrop that supports long-term revenue durability for approved assets.
Investor Outlook
Exelixis, Inc. (EXEL) carries a Weiss Rating of B (Buy), but the path forward hinges significantly on the FDA's decision on the zanzalintinib NDA, with a target action date of December 3, 2026 — a binary catalyst that will either validate the pipeline diversification thesis or extend the company's dependence on CABOMETYX. Investors should watch for any additional subgroup data or agency communications ahead of that date, as well as continued CABOMETYX revenue trends through the back half of 2026. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--